CCXI News and Press, ChemoCentryx Inc. From 08/09/22

SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 20...

Amgen has seen stagnation in recent years, as it has been pursuing M&A to bolster the pipeline and reignite growth. Deals still have to make a contribution, as stagnating sales, buybacks, deals and an IRS issue increase leverage quite a bit. I like the modest valuation here, a...

The biotech industry for the first half of the year had seen better six-month periods in the past, but the situation appears to have changed beginning in July. From Jan. 1 to June 20, 2022, the SPDR S&P Biotech ETF ( XBI ) and iShares Nasdaq Biotechnology ETF ( IBB ) had...

The major U.S. equity averages posted a mixed performance on Thursday, as investors bided their time ahead of a key employment report due out before Friday's open. The Nasdaq edged higher, while the Dow and S&P 500 dipped. Although most of the market saw lackluster trading, ChemoCen...

Gainers: InVivo Therapeutics Holdings ( NVIV ) +164% . ChemoCentryx ( CCXI ) +109% . Minerva Neurosciences ( NERV ) +104% . Missfresh ( MF ) +66% . Society Pass ( SOPA ) +49% . Greenpro Capital ( GRNQ ) +48% . Yel...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips <img width="1600" height="900" class="aligncenter size-full wp-image-1630608" src="https://investorplace.com/wp-content/uploads/2020/06/nkla-stock-1600.png" alt="Nikola ( NKLA ) badge on the front of a matte black car...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock ChemoCentryx (NASDAQ: CCXI ) stock is rocketing higher on Thursday as investors react to news of an acquisition deal with Amgen (NASDAQ: AMGN ). This deal has Amgen agreeing to acq...

Shares of ChemoCentryx (NASDAQ: CCXI) skyrocketed by as much as 110% in premarket trading Thursday morning. The company's stock bolted higher following the news that biotech heavyweight Amgen (NASDAQ: AMGN) offered $3.7 billion in cash to acquire the rare-disease special...

Gainers: InVivo Therapeutics ( NVIV ) +114% . ChemoCentryx CCXI +108% . GreenLight Biosciences ( GRNA ) +56% . Global Blood Therapeutics GBT +37% . NanoViricides ( NNVC ) +29% . Losers: Helius Medical Technologies ( HSDT...

Amgen ( NASDAQ: AMGN ) has agreed to buy ChemoCentryx ( CCXI ), a drug developer focused on autoimmune disorders, for $3.7B in cash, the companies announced on Thursday in an emailed statement. ChemoCentryx ( CCXI ) shares jumped ~109% after the news. Amgen ( ...